Diagens Tech chair says medical AI future favors clinician-customized copilots over single model

By Public Technologies
  • Diagens Tech management outlined a strategy to scale medical imaging AI through continuous model creation, not reliance on a single “best” system.
  • Chairman Ning Song backed a diversified approach, where specialist radiologists train bespoke AI copilots on the iMedImage foundation model.
  • Management positioned iMedLoop as an end-to-end platform linking data generation, model training, evaluation, deployment, and feedback to drive a data flywheel.
  • Kevin Kelly framed the shift as “AI does medicine, humans do doctoring,” leaving clinicians to focus on judgement, empathy, and patient support.
  • Diagens Tech highlighted a new joint laboratory with Hong Kong Polytechnic University to build talent for AI-enabled medical applications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Diagens Biotechnology Co. Ltd. published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2406632_en) on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.